Effective January 1, 2017 - New permanent J-code for ONIVYDE: J9205, injection, irinotecan liposome, 1 mg This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.

FOR US HEALTHCARE PROFESSIONALS ONLY Call Us at (844) 441-6225

Expert Videos & Resources

The following video chapters were previously recorded as part of a live, national broadcast event. Expert oncologists review the results of the NAPOLI-1 Phase 3 trial that supported the approval of ONIVYDE® (irinotecan liposome injection) and share details about the key efficacy, safety, and recommended dosing information. They will also present a patient case study and discuss the potential integration of this therapy into clinical practice.

In the Resources section below these videos, please review the published NAPOLI-1 study in The Lancet. If you do not have individual or institutional access to this journal, please contact us for a copy of the article.

1. Introducing ONIVYDE® (irinotecan liposome injection)

Oncologists discuss the indication, structure, and mechanism of delivery of ONIVYDE, an encapsulation of irinotecan in a long-circulating liposome.

RESOURCES

INDICATION AND IMPORTANT SAFETY INFORMATION

**National Comprehensive Cancer Network® (NCCN®).

EXPAND

INDICATION AND IMPORTANT
SAFETY INFORMATION